Journal of Clinical Endocrinology & Metabolism, Vol 48, 572-576, Copyright © 1979 by Endocrine Society

ARTICLES

Changes in thyroid-stimulating immunoglobulins during antithyroid therapy

G Fenzi, K Hashizume, CP Roudebush and LJ DeGroot

Thyroid-stimulating immunoglobulin (TSI) activity was measured by radioreceptor assay in sera from patients with Graves' disease, Hashimoto's thyroiditis, and thyroid cancer. In untreated Graves' disease (47 cases), TSI index was significantly lower [76.7 +/- 1.4 (SE)] than the average of a normal control group (30 cases; 94.4 +/- 1.9). In untreated Hashimoto's thyroiditis (25 cases), it was also significantly lower (83.0 +/- 2.4). In patients with thyroid cancer (19 cases), there was no significant difference from normal controls. After 131I treatment, the TSI index in Graves' disease decreased during 2--4 months, then increased and reached normal levels in 1 yr. During propylthiouracil treatment, the TSI index increased and reached a normal level in 5--6 months without the decreasing phase seen after 131I treatment. Free T4 index values were gradually decreased by both treatments. There was no significant relationship between TSI index and thyroid antibodies (microsomal antibodies and thyroglobulin antibodies) in untreated Graves' disease or Hashimoto's thyroiditis. It is concluded that 1) in the sera of patients with Graves' disease and Hashimoto's thyroiditis, there are immunoglobulin Gs that can displace TSH binding to thyroid membranes; 2) these immunoglobulins Gs are different from the classic antithyroid antibodies; and 3) 131T treatment of Graves' disease may enhance TSI production during the first 1--2 months after therapy.

This article has been cited by other articles:

				L. Agate, S. Mariotti, R. Elisei, P. Mossa, F. Pacini, E. Molinaro, L. Grasso, L. Masserini, T. Mokhort, T. Vorontsova, et al. Thyroid Autoantibodies and Thyroid Function in Subjects Exposed to Chernobyl Fallout during Childhood: Evidence for a Transient Radiation-Induced Elevation of Serum Thyroid Antibodies without an Increase in Thyroid Autoimmune Disease J. Clin. Endocrinol. Metab., July 1, 2008; 93(7): 2729 - 2736. [Abstract] [Full Text] [PDF]

				A Boschi, C. Daumerie, M Spiritus, C Beguin, M Senou, D Yuksel, M Duplicy, S Costagliola, M Ludgate, and M C Many Quantification of cells expressing the thyrotropin receptor in extraocular muscles in thyroid associated orbitopathy Br. J. Ophthalmol., June 1, 2005; 89(6): 724 - 729. [Abstract] [Full Text] [PDF]

				M. Kazim, R. A. Goldberg, and T. J. Smith Insights Into the Pathogenesis of Thyroid-Associated Orbitopathy: Evolving Rationale for Therapy Arch Ophthalmol, March 1, 2002; 120(3): 380 - 386. [Full Text] [PDF]

				J. Pritchard, N. Horst, W. Cruikshank, and T. J. Smith Igs from Patients with Graves' Disease Induce the Expression of T Cell Chemoattractants in Their Fibroblasts J. Immunol., January 15, 2002; 168(2): 942 - 950. [Abstract] [Full Text] [PDF]